Correspondence 0001193125-23-182477 from Lyra Therapeutics, Inc. (LYRA)
Lyra Therapeutics, Inc.
Date: July 6, 2023 · CIK: 0001327273 · Accession: 0001193125-23-182477
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-272981
Letter
Lyra Therapeutics, Inc.
480 Arsenal Way
Watertown, MA
July 6, 2023
Via EDGAR
Securities and Exchange Commission
Division of Corporation Finance
Office of Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: Ben Richie
Re: Lyra Therapeutics, Inc.
Registration Statement on Form S-3 Filed June 28, 2023
File No. 333-272981
To whom it may concern:
Pursuant to Rule 461(a) under the Securities Act of 1933, as amended, Lyra Therapeutics, Inc. (the “Company”) hereby respectfully requests that the effective date of the Company’s Registration Statement on Form S-3 (File No. 333-272981) be accelerated by the Securities and Exchange Commission to 4:30 p.m. Washington D.C. time on July 7, 2023 or as soon as practicable thereafter.
The Company requests that we be notified of such effectiveness by a telephone call to Wesley C. Holmes of Latham & Watkins LLP at (617) 948-6027 and that such effectiveness also be confirmed in writing.
Very truly yours,
Lyra Therapeutics, Inc.
Show Raw Text
CORRESP 1 filename1.htm CORRESP Lyra Therapeutics, Inc. 480 Arsenal Way Watertown, MA 02472 July 6, 2023 Via EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Ben Richie Re: Lyra Therapeutics, Inc. Registration Statement on Form S-3 Filed June 28, 2023 File No. 333-272981 To whom it may concern: Pursuant to Rule 461(a) under the Securities Act of 1933, as amended, Lyra Therapeutics, Inc. (the “Company”) hereby respectfully requests that the effective date of the Company’s Registration Statement on Form S-3 (File No. 333-272981) be accelerated by the Securities and Exchange Commission to 4:30 p.m. Washington D.C. time on July 7, 2023 or as soon as practicable thereafter. The Company requests that we be notified of such effectiveness by a telephone call to Wesley C. Holmes of Latham & Watkins LLP at (617) 948-6027 and that such effectiveness also be confirmed in writing. Very truly yours, Lyra Therapeutics, Inc. By: /s/ Jason Cavalier Jason Cavalier Chief Financial Officer cc: Wesley C. Holmes, Latham & Watkins LLP